Tara L. Kieffer was named Chief Operating Officer of Enanta Pharmaceuticals Inc. As of November 4, 2026, Enanta Pharmaceuticals Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 28, 2026, naming 1 appointment (Form 8-K, October 28, 2026).
Sell to companies like Enanta Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Enanta Pharmaceuticals Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-28. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Enanta Pharmaceuticals Inc files it.
Also on the record for Enanta Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock Portfolio Management LLC | 5.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 4.97% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Farallon Capital Management, L.L.C. | 8.3% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 6.78% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by Dapice Joshua J. | 9.8% of the class | 5%+ stakes | Source |
| January 20, 2026 | Stake report, Schedule 13G/A, by Integrated Core Strategies (US) LLC | 2.3% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Millennium Management LLC | 4.1% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC | 12.1% of the class | 5%+ stakes | Source |
| October 9, 2025 | Stake report, Schedule 13G, by Deep Track Capital, LP | 5.33% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Enanta Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Enanta Pharmaceuticals Inc and the records around it.
Enanta Pharmaceuticals Inc elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Aug 2026), InflaRx N.V. (Aug 2026), Savara Inc. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Enanta Pharmaceuticals Inc
Get an email when Enanta Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Enanta Pharmaceuticals Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Enanta Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Enanta Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-28 | In | Chief Operating Officer | 8-K, 2026-10-28 |
Who leads Enanta Pharmaceuticals Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Tara L. Kieffer, appointed (filed 2026-10-28).
New leaders reset buying decisions — get the Full Report on Enanta Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Enanta Pharmaceuticals Inc, with the record behind each one.
Find candidates like Chief Operating Officer at Enanta Pharmaceuticals IncEvery change, in the filing's words
Appointed: Tara L. Kieffer, Chief Operating Officer
In addition, on October 28, 2026, the Board appointed Tara L. Kieffer, Ph.D., to the newly created role of Chief Operating Officer.
- On October 28, 2026, Enanta Pharmaceuticals, Inc. (the "Company") and Jay R. Luly, Ph.D., age 70, announced Dr. Luly's intention to retire as President and Chief Executive Officer by February 1, 2027, following 23 years of leadership with the Company.
- The Company expects to enter into an agreement with Dr. Luly for his continued service as a strategic advisor for the remainder of 2027.
- The Board of Directors (the "Board") of the Company has initiated a comprehensive search for Dr. Luly's successor, considering both internal and external candidates.
- Dr. Kieffer has not entered into any material plan, contract, arrangement or amendment in connection with this appointment.
Tools for this story
Each opens in a new tab, filled in for Enanta Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.